

Joshua T Cohen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8012525/joshua-t-cohen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

145
papers

5,693
citations

36
h-index

73
g-index

154
ext. papers

6,765
ext. citations

6.1
avg, IF

6.08
L-index

#	Paper	IF	Citations
145	Updating cost-effectiveness--the curious resilience of the \$50,000-per-QALY threshold. <i>New England Journal of Medicine</i> , 2014 , 371, 796-7	59.2	1343
144	Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2007 , 10 Suppl 1, 1-269	8.6	559
143	Does preventive care save money? Health economics and the presidential candidates. <i>New England Journal of Medicine</i> , 2008 , 358, 661-3	59.2	287
142	A quantitative risk-benefit analysis of changes in population fish consumption. <i>American Journal of Preventive Medicine</i> , 2005 , 29, 325-34	6.1	172
141	A quantitative analysis of fish consumption and coronary heart disease mortality. <i>American Journal of Preventive Medicine</i> , 2005 , 29, 335-46	6.1	140
140	A quantitative analysis of prenatal intake of n-3 polyunsaturated fatty acids and cognitive development. <i>American Journal of Preventive Medicine</i> , 2005 , 29, 366-74	6.1	131
139	Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. <i>Circulation</i> , 2011 , 123, 1911-8	16.7	111
138	A quantitative analysis of prenatal methyl mercury exposure and cognitive development. <i>American Journal of Preventive Medicine</i> , 2005 , 29, 353-65	6.1	106
137	Noncancer Risk Assessment: A Probabilistic Alternative to Current Practice. <i>Human and Ecological Risk Assessment (HERA)</i> , 1996 , 2, 79-102	4.9	105
136	Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1271-7	15.1	97
135	Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. <i>Health Economics (United Kingdom)</i> , 2012 , 21, 238-51	2.4	94
134	Vascular access choice in incident hemodialysis patients: a decision analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 183-91	12.7	89
133	Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. <i>Alzheimer's and Dementia</i> , 2013 , 9, 30-8	1.2	89
132	A comprehensive evaluation of the potential health risks associated with occupational and environmental exposure to styrene. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2002 , 5, 1-265	8.6	86
131	A quantitative analysis of fish consumption and stroke risk. <i>American Journal of Preventive Medicine</i> , 2005 , 29, 347-52	6.1	83
130	3385 TARGETING DIABETES PREVENTION PROGRAMS: INDIVIDUAL RISK-BASED HEALTH ECONOMIC ANALYSIS. <i>Journal of Clinical and Translational Science</i> , 2019 , 3, 155-156	0.4	78
129	Weight of the Evidence Evaluation of Low-Dose Reproductive and Developmental Effects of Bisphenol A. <i>Human and Ecological Risk Assessment (HERA)</i> , 2004 , 10, 875-921	4.9	76

128	QALYs in 2018-Advantages and Concerns. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2473-2474	27.4	75
127	The changing face of the cost-utility literature, 1990-2012. <i>Value in Health</i> , 2015 , 18, 271-7	3.3	71
126	Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. <i>Value in Health</i> , 2018 , 21, 759-761	3.3	71
125	Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. <i>Journal of Vascular Surgery</i> , 2012 , 56, 1015-24.e1	3.5	71
124	When is evidence sufficient?. <i>Health Affairs</i> , 2005 , 24, 93-101	0	65
123	Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. <i>Pediatrics</i> , 2012 , 129, e999-1010	7.4	63
122	A revised economic analysis of restrictions on the use of cell phones while driving. <i>Risk Analysis</i> , 2003 , 23, 5-17	3.9	57
121	30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. <i>Pharmacoeconomics</i> , 2009 , 27, 861-72	4.4	56
120	A clinical and economic evaluation of enteral nutrition. <i>Current Medical Research and Opinion</i> , 2011 , 27, 413-22	2.5	52
119	A systematic review of the evidence concerning the economic impact of employee-focused health promotion and wellness programs. <i>Journal of Occupational and Environmental Medicine</i> , 2013 , 55, 209-22 ²		51
118	When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. <i>PLoS Medicine</i> , 2017 , 14, e1002397	11.6	48
117	Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2018 , 168, 161-169	8	48
116	A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. <i>PLoS ONE</i> , 2016 , 11, e0168512	3.7	46
115	Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. <i>Circulation</i> , 2012 , 125, 2621-9	16.7	44
114	The empirical basis for determinations of medical futility. <i>Journal of General Internal Medicine</i> , 2010 , 25, 1083-9	4	44
113	Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining. <i>Genetics in Medicine</i> , 2012 , 14, 663-9	8.1	43
112	Dependence as a unifying construct in defining Alzheimer@ disease severity. <i>Alzheimer@ and Dementia</i> , 2010 , 6, 482-93	1.2	43
111	Comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 506-13	5.8	38

110	Decision analytic models for Alzheimer's disease: state of the art and future directions. <i>Alzheimer's and Dementia</i> , 2008 , 4, 212-22	1.2	36
109	Fuels for urban transit buses: a cost-effectiveness analysis. <i>Environmental Science & Technology</i> , 2003 , 37, 1477-84	10.3	36
108	Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018. <i>Pharmacoeconomics</i> , 2020 , 38, 1135-1145	11.45	33
107	The influence of time horizon on results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 615-623	2.2	32
106	Comparing patient access to pharmaceuticals in the UK and US. <i>Applied Health Economics and Health Policy</i> , 2006 , 5, 177-87	3.4	30
105	Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1174-1178	1.2	29
104	Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. <i>Value in Health</i> , 2017 , 20, 200-205	3.3	28
103	The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. <i>Applied Health Economics and Health Policy</i> , 2017 , 15, 75-83	3.4	28
102	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <i>Blood</i> , 2015 , 125, 1866-9	2.2	27
101	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1823-9	4.7	26
100	The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	26
99	Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. <i>Value in Health</i> , 2015 , 18, 308-14	3.3	25
98	Medicare is scrutinizing evidence more tightly for national coverage determinations. <i>Health Affairs</i> , 2015 , 34, 253-60	7	24
97	Diesel vs. compressed natural gas for school buses: a cost-effectiveness evaluation of alternative fuels. <i>Energy Policy</i> , 2005 , 33, 1709-1722	7.2	24
96	Policy: Rethink chemical risk assessments. <i>Nature</i> , 2012 , 489, 27-8	50.4	22
95	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , 2019 , 14, e0205633	3.7	21
94	Little evidence of correlation between growth in health care spending and reduced mortality. <i>Health Affairs</i> , 2010 , 29, 1523-31	7	20
93	The development of a stochastic physiologically-based pharmacokinetic model for lead. <i>Science of the Total Environment</i> , 2001 , 274, 15-9	10.2	19

92	Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer disease. <i>Health Affairs</i> , 2014 , 33, 547-54	7	18
91	Life years lost at hazardous waste sites: remediation worker fatalities vs. cancer deaths to nearby residents. <i>Risk Analysis</i> , 1997 , 17, 419-25	3.9	18
90	Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. <i>Journal of General Internal Medicine</i> , 2020 , 35, 2629-2636	4	17
89	Low-value services in value-based insurance design. <i>American Journal of Managed Care</i> , 2010 , 16, 280-6	2.1	17
88	Evaluation of the economic burden of diseases associated with poor nutrition status. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014 , 38, 355-415	4.2	16
87	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 931-40	2.2	16
86	An Arsenic Exposure Model: Probabilistic Validation Using Empirical Data. <i>Human and Ecological Risk Assessment (HERA)</i> , 1998 , 4, 341-377	4.9	16
85	Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. <i>Health Affairs</i> , 2021 , 40, 53-61	7	16
84	Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures. <i>Value in Health</i> , 2013 , 16, 629-38	3.3	15
83	What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). <i>Health Affairs</i> , 2007 , 26, 636-46	7	14
82	Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. <i>Value in Health</i> , 2017 , 20, 193-199	3.3	13
81	Cardiac screening prior to stimulant treatment of ADHD: a survey of US-based pediatricians. <i>Pediatrics</i> , 2012 , 129, 222-30	7.4	13
80	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018 , 2, 5	2.4	13
79	Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1972-1973	27.4	12
78	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, S34-S48	1.9	12
77	Patient Variability Seldom Assessed in Cost-effectiveness Studies. <i>Medical Decision Making</i> , 2018 , 38, 487-494	2.5	12
76	What is the value of oncology medicines?. <i>Nature Biotechnology</i> , 2010 , 28, 1160-3	44.5	12
75	Health trade-offs from policies to alter fish consumption. <i>American Journal of Preventive Medicine</i> , 2005 , 29, 324	6.1	12

74	Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response. <i>Medical Care</i> , 2017 , 55, 912-914	3.1	11
73	Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2019 , 15, e948-e956	3.1	11
72	Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 36, 96-103	1.8	11
71	A primer on cost-effectiveness analyses for vascular surgeons. <i>Journal of Vascular Surgery</i> , 2012 , 55, 1794-800	3.9	11
70	Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 595-603	2.2	11
69	Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007. <i>Medical Care</i> , 2016 , 54, 380-5	3.1	10
68	Trends of cost-effectiveness studies in sleep medicine. <i>Sleep Medicine</i> , 2019 , 53, 176-180	4.6	10
67	The adoption of cost-effectiveness acceptability curves in cost-utility analyses. <i>Medical Decision Making</i> , 2010 , 30, 314-9	2.5	10
66	Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008 , 1, 134-7	5.8	10
65	Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018 , 2, 5	2.4	9
64	Dementia Diagnosis Disparities by Race and Ethnicity. <i>Medical Care</i> , 2021 , 59, 679-686	3.1	9
63	Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	8
62	ICER's Revised Value Assessment Framework for 2017-2019: A Critique. <i>Pharmacoeconomics</i> , 2017 , 35, 977-980	4.4	8
61	Cost-effectiveness of cardiovascular disease spending. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2123-4	15.1	8
60	Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 513-22	2.2	8
59	Racial and Ethnic Differences in Knowledge About One's Dementia Status. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 1763-1770	5.6	7
58	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018 , 182, 212-221	4.5	7
57	Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015 , 109, 379-85	2	7

56	A role for research: an observation on preventive services for women. <i>American Journal of Preventive Medicine</i> , 2013 , 44, S12-5	6.1	7
55	Likelihood Ratio Analysis of Skin Cancer Prevalence Associated with Arsenic in Drinking Water in the USA. <i>Environmental Geochemistry and Health</i> , 1998 , 20, 61-66	4.7	7
54	Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 627-638	1.9	6
53	Using decision analysis to better evaluate pediatric clinical guidelines. <i>Health Affairs</i> , 2008 , 27, 1467-75	7	6
52	Preparing the health-care system to pay for new Alzheimer's drugs. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1568-1570	1.2	6
51	The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. <i>Health Research Policy and Systems</i> , 2016 , 14, 86	3.7	6
50	O2-11-01: National Estimates of Potentially Avoidable Hospitalizations among Medicare Beneficiaries with Alzheimer's Disease and Related Dementias 2016 , 12, P253-P254		6
49	Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. <i>Pharmacoeconomics</i> , 2016 , 34, 1255-1265	4.4	6
48	Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. <i>Health Affairs</i> , 2019 , 38, 60-67	7	6
47	Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. <i>Medical Decision Making</i> , 2017 , 37, 790-801	2.5	5
46	Are low and middle-income countries prioritising high-value healthcare interventions?. <i>BMJ Global Health</i> , 2020 , 5, e001850	6.6	5
45	The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014 , 4, 494-508	2.5	5
44	Unintended consequences of the potential phase-out of gamma irradiation. <i>F1000Research</i> , 2018 , 7, 348	3.6	5
43	Measuring "Fearonomic Effects" in Valuing Therapies: An Application to COVID-19 in China. <i>Value in Health</i> , 2020 , 23, 1405-1408	3.3	5
42	Cost-effectiveness analysis of three algorithms for diagnosing primary ciliary dyskinesia: a simulation study. <i>Orphanet Journal of Rare Diseases</i> , 2019 , 14, 142	4.2	4
41	Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S. <i>Oncologist</i> , 2020 , 25, e1117-e1119	5.7	4
40	A Call for Open-Source Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2018 , 168, 529	8	4
39	Survey of United States child and adolescent psychiatrists' cardiac screening practices prior to starting patients on stimulants. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012 , 22, 375-84	2.9	4

38	Author response: Risks and Benefits of Seafood Consumption. <i>American Journal of Preventive Medicine</i> , 2006 , 30, 441-443	6.1	4
37	Dementia diagnosis disparities by race and ethnicity. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043183	1.2	4
36	Publication of Decision Model Source Code: Attitudes of Health Economics Authors. <i>Pharmacoeconomics</i> , 2019 , 37, 1409-1410	4.4	3
35	Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. <i>Journal of Medical Economics</i> , 2011 , 14, 187-93	2.4	3
34	Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective. <i>American Journal of Kidney Diseases</i> , 2007 , 50, 362-5	7.4	3
33	Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?. <i>New England Journal of Medicine</i> , 2021 , 385, 1923-1924	59.2	3
32	A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. <i>Value in Health</i> , 2018 , 21, 400-406	3.3	2
31	Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?. <i>Value in Health</i> , 2019 , 22, 1396-1401	3.3	2
30	Economic Evaluation in Adolescent and Young Adult Cancer: Methodological Considerations and the State of the Science. <i>Pediatric Oncology</i> , 2017 , 779-799	0.5	2
29	FDA proposed ban on trans fats: How do the costs and benefits stack up?. <i>Clinical Therapeutics</i> , 2014 , 36, 322-7	3.5	2
28	Value-based drug pricing in the Biden era: Opportunities and prospects. <i>Health Services Research</i> , 2021 , 56, 1093-1099	3.4	2
27	Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , 2016 , 2016, 3645623		2
26	Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1976-1980	1.9	2
25	Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions.. <i>Genetics in Medicine</i> , 2022 ,	8.1	2
24	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018 , 169, 200-201	8	1
23	Pediatric Lipid Screening and Treatment for Cardiovascular Disease Prevention: An Ounce or a Pound?. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 261-269	0.9	1
22	Cost estimation of first-line antiretroviral therapy with zidovudine/stavudine as the nucleoside backbone in India: a pilot study. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015 , 14, 180-4	1.7	1
21	Imputing productivity gains from clinical trials. <i>Journal of Occupational and Environmental Medicine</i> , 2012 , 54, 826-33	2	1

20	The use of Monte Carlo simulation techniques to predict population blood lead levels. <i>Environmental Geochemistry and Health</i> , 1994 , 16, 197-215	4.7	1
19	Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. <i>Vaccine</i> , 2021 , 39, 6727-6734	4.1	1
18	Optimizing Decision Making in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020 , 265-273	0	1
17	Is the high cost of CML care "worth it"?. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17801-e17801	2.2	1
16	Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. <i>Acta Diabetologica</i> , 2021 , 58, 707-722	3.9	1
15	Do Cost-Effectiveness Analyses Account for Drug Genericism? A Literature Review and Assessment of Implications.. <i>Value in Health</i> , 2022 , 25, 59-68	3.3	0
14	Are Medical Devices Cost-Effective?. <i>Applied Health Economics and Health Policy</i> , 2021 , 1	3.4	0
13	The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20019-e20019	2.2	0
12	Hospital Care at Home: Better, Cheaper, Faster?. <i>Annals of Internal Medicine</i> , 2020 , 172, 145-146	8	0
11	Price and value in cancer care. <i>Cancer</i> , 2015 , 121, 4097-8	6.4	
10	Dioxin toxicity. <i>Risk Analysis</i> , 2010 , 30, 1457-8	3.9	
9	Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6512-6512	2.2	
8	Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18887-e18887	2.2	
7	Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 12068-12068	2.2	
6	Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT) in elderly patients with multiple myeloma (MM) using the SEER-Medicare database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8517-8517	2.2	
5	An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. <i>Blood</i> , 2015 , 126, 2635-2635	2.2	
4	Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review. <i>Blood</i> , 2016 , 128, 3564-3564	2.2	
3	Validity and reliability of four value frameworks for cancer drugs.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6603-6603	2.2	

- 2 Network meta-analysis of adjuvant chemotherapy in early breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, e12071-e12071 2.2
- 1 Bovine Spongiform Encephalopathy: Risk Assessment and Governmental Policy303-312